Synonym
LY 186126; LY186126; LY-186126.
IUPAC/Chemical Name
2H-Indol-2-one, 1,3-dihydro-1,3,3-trimethyl-5-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)-
InChi Key
KYKHXPMUZAMXTE-UHFFFAOYSA-N
InChi Code
InChI=1S/C16H19N3O2/c1-9-7-13(20)17-18-14(9)10-5-6-12-11(8-10)16(2,3)15(21)19(12)4/h5-6,8-9H,7H2,1-4H3,(H,17,20)
SMILES Code
O=C1N(C)C2=C(C=C(C(C(C)C3)=NNC3=O)C=C2)C1(C)C
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
285.34
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Ashikaga T, Robertson DW, Sportsman RJ, Strada SJ, Thompson WJ. Comparison of indolidan analog binding sites of drug antibody and sarcoplasmic reticulum with inhibition of cyclic AMP phosphodiesterase. J Recept Signal Transduct Res. 1996 Sep-Nov;16(5-6):315-37. PubMed PMID: 8968964.
2: Lugnier C, Muller B, Le Bec A, Beaudry C, Rousseau E. Characterization of indolidan- and rolipram-sensitive cyclic nucleotide phosphodiesterases in canine and human cardiac microsomal fractions. J Pharmacol Exp Ther. 1993 Jun;265(3):1142-51. PubMed PMID: 8389853.
3: Flawn P, Loten EG. Properties and distribution of cyclic AMP phosphodiesterase from rat liver. Int J Biochem. 1990;22(9):983-8. PubMed PMID: 1704319.
4: Artman M, Robertson DW, Mahony L, Thompson WJ. Analysis of the binding sites for the cardiotonic phosphodiesterase inhibitor [3H]LY186126 in ventricular myocardium. Mol Pharmacol. 1989 Aug;36(2):302-11. PubMed PMID: 2505059.
5: Robertson DW, Krushinski JH, Utterback BG, Kauffman RF. Synthesis of a tritium-labeled indolidan analogue and its use as a radioligand for phosphodiesterase-inhibitor cardiotonic binding sites. J Med Chem. 1989 Jul;32(7):1476-80. PubMed PMID: 2738882.
6: Kauffman RF, Utterback BG, Robertson DW. Characterization and pharmacological relevance of high affinity binding sites for [3H]LY186126, a cardiotonic phosphodiesterase inhibitor, in canine cardiac membranes. Circ Res. 1989 Jul;65(1):154-63. PubMed PMID: 2544318.
7: Kauffman RF, Utterback BG, Robertson DW. Specific binding of [3H]LY186126, an analogue of indolidan (LY195115), to cardiac membranes enriched in sarcoplasmic reticulum vesicles. Circ Res. 1989 May;64(5):1037-40. PubMed PMID: 2539921.
